Trump Praises PM Modi Drug Crackdown Despite India's Inclusion on US Transit List

The Paradox: Presidential Praise vs. Official Listing

On September 16, 2026, US President Donald Trump issued a Presidential Determination to Congress that identified India as one of 23 major drug transit or illicit drug-producing countries. While such a designation might appear critical, the official directive contained a striking paradox: Trump explicitly commended the leadership of Prime Minister Narendra Modi.

The US President expressed support for the specific measures taken by New Delhi to combat illegal poppy farming and strengthen the integrity of supply chains [1]. This distinction suggests that while the US views India's geography as a vulnerability, it views PM Modi's policy execution as a success.

Why India is Listed as a 'Drug Transit' Country

To understand why India remains on this list despite receiving high-level praise, it is necessary to distinguish between government effort and geographic reality. The US government clarified that being named a transit hub does not mean the Indian government is failing in its duties.

According to the determination, these designations are driven by a mix of economic, commercial, and geographic factors that make a territory susceptible to the movement of precursor chemicals or finished narcotics [2]. Essentially, India's position as a global trade hub and its borders make it a natural target for traffickers, regardless of how strict the law enforcement measures are.

The 2026 Major Drug Transit List: Global Context

India is not alone in this designation. The September 2026 list includes 23 nations across several continents, highlighting a global struggle with synthetic drugs and narcotics:

• Asian Nations: India, China, Pakistan, Afghanistan, Burma, and Laos.
• Americas: Mexico, Colombia, Venezuela, Bolivia, Peru, Ecuador, Guatemala, Haiti, Honduras, Nicaragua, Panama, Costa Rica, Belize, The Bahamas, Dominican Republic, El Salvador, and Jamaica.

Strengthening the US-India Counter-Narcotics Alliance

The relationship between Washington and New Delhi on this front has evolved into a structured strategic partnership. This is primarily managed through the United States-India Drug Policy Framework and a specialized Drug Policy Executive Working Group created earlier in 2026 [2].

This collaboration focuses on three critical areas to prevent the exploitation of legal channels for illegal ends:

1. Narcotics Trafficking: Disrupting the physical movement of drugs across international borders.
2. Precursor Chemical Control: Monitoring the chemicals used to synthesize deadly drugs like fentanyl (an area where Trump also pressured China to act).
3. Pharmaceutical Security: Protecting the legal medicine supply chain from being diverted into the black market.

By separating the geographic risk from the political will, the US administration has signaled that its cooperation with PM Modi is a central pillar of its broader 2026 National Drug Control Strategy.